期刊文献+

地西他滨联合常规化疗方案对骨髓增生异常综合征的临床疗效观察 被引量:2

Clinical Observation of Decitabine Combined with Conventional Chemotherapy Regimen on Myelodysplastic Syndrome
下载PDF
导出
摘要 目的:探究地西他滨联合常规化疗方案对骨髓增生异常综合征的临床疗效观察。方法:选择某院接治的骨髓增生异常综合征患者60例为研究对象,对照组与观察组各30例,比较两组的临床疗效结果。结果:通过两组患者治疗前后发现,两组差异具有统计学意义。结论:应用地西他滨联合常规化疗方案治疗骨髓增生异常综合征具有疗效好的优点,值得广泛采用。 Objective:To investigate the clinical effect of decitabine combined with conventional chemotherapy regimen on myelodysplastic syndrome.Methods:60 patients with myelodysplastic syndromes were selected as the study subjects,with 30 cases in the control group and the observation group respectively.Results:Before and after treatment,the difference between the two groups was statistically significant.Conclusion:The application of decitabine combined with conventional chemotherapy in the treatment of myelodysplastic syndromes has the advantages of good curative effect and is worthy of widely application.
出处 《数理医药学杂志》 2017年第7期1035-1036,共2页 Journal of Mathematical Medicine
基金 广东省中山市科技局课题(编号:2014A1FC061)
关键词 地西他滨 常规化疗 骨髓增生异常综合征 疗效观察 decitabine conventional chemotherapy myelodysplastic syndrome efficacy observation
  • 相关文献

参考文献8

二级参考文献102

  • 1ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病.淋巴瘤,2004,13(4):246-250. 被引量:31
  • 2Shen L,Kantarjian H,Guo Y,et al.DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes[J].J Clin Oncol,2010,28(4):605-13.
  • 3Garcia JS,Jain N,Godley LA.An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes[J]. Onco Targets Ther,2010,3(3):1-13.
  • 4Sekeres MA.Treatment of MDS:something old,something new, something borrowed[C].Am Soc Hematol Educ Program.2009: 656-63.
  • 5Momparler RL.Pharmacology of 5-aza-2'-deoxycytidine(decitabine) [J].Semin Hematol,2005,42(1):S9-S16.
  • 6Oki Y,Aoki E,Issa JP.Decitabine-bedside to bench[J].Crit Rev Oncol Henatol,2007,61(2):140-52.
  • 7Bhalla KN.Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies[J].J Clin Oncol,2005,23:3971-93.
  • 8Kantarjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higherrisk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109(1):52-7.
  • 9Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996.
  • 10张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281.

共引文献161

同被引文献17

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部